title: Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.
abstract: Antiviral therapy with interferon based therapies (IBT) has shown potential in improving survival in patients who have undergone resection or locoregional therapy for hepatitis C-associated hepatocellular carcinoma (HCV-HCC). However, this benefit has not been definitively ascribed to sustained viral response (SVR). Since IBT has been replaced with new directly acting agents (DAA), which are more efficacious in the treatment of HCV, we sought to better determine the prognostic impact of SVR in HCV-HCC. A systematic search of MEDLINE and EMBASE from inception through October 2015 was performed to identify studies that described the impact of presence of SVR in patients who underwent curative treatment of HCV-HCC. Summary hazard ratio (HR) with 95% confidence intervals (CI) was estimated for recurrence-free survival (RFS) and overall survival (OS) utilizing a random-effects model. After reviewing 858 abstracts, ten studies which included a total of 1,794 patients were selected and data was extracted. Of these ten studies, the impact of SVR on RFS and OS was reported in eight and seven studies respectively. In a meta-analysis which included 1,519 patients, SVR was associated with improved OS (HR 0.18; 95% CI 0.11-0.29, I2= 2%). We also found that SVR was associated with better RFS in a meta-analysis (1,241 patients; HR 0.50; 95% CI 0.40-0.63, I2= 0). In conclusion, SVR is associated with improved OS and RFS in patients with HCV who have undergone resection or locoregional therapy for HCC. Newer DAA therapies which offer increased tolerability and viral eradication should be considered as adjunctive therapy.
authors.affiliation: Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO.
authors.forename: Sashidhar
authors.identifier: http://orcid.org/0000-0001-9588-2744
authors.initials: S
authors.lastname: Manthravadi
authors.affiliation: Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
authors.forename: Swathi
authors.initials: S
authors.lastname: Paleti
authors.affiliation: Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.|Division of Gastroenterology, Kansas City VA Medical Center, Kansas City, MO.
authors.forename: Prashant
authors.initials: P
authors.lastname: Pandya
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology* / Q000401:mortality / Q000601:surgery / Q000821:virology; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000209:etiology* / Q000401:mortality / Q000601:surgery / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents; D007372:Interferons
keywords: hepatitis C; hepatocellular carcinoma; meta-analysis; sustained viral response